Valion Bio, Shear Kershman complete oral mucosal Entolimod formulation milestone

• Valion Bio reported successful formulation of an oral mucosal Entolimod using Shear Kershman’s BioViscid drug-delivery platform.
• Program targets a needle-free delivery route for the radiation countermeasure, potentially widening deployment in radiological or nuclear emergencies.
• Next milestone shifts to testing whether oral mucosal dosing achieves measurable systemic exposure, with pharmacokinetics guiding dose and formulation optimization.
• Management estimated a fully developed oral mucosal product could expand potential U.S. dose requirements by about 10 to 40 times.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609300745ACCESSWRNAPR_____1228892) on September 30, 2026, and is solely responsible for the information contained therein.